MS15 (TFA)

• Description :

  MS15 TFA is a potent and selective AKT PROTAC degrader. MS15 TFA inhibits the AKT1, -2, and -3 activities, with IC50 values of 798 nM, 90 nM, and 544 nM, respectively[1].

• UNSPSC :

  12352005

• Target :

  Akt; PROTACs

• Type :

  Reference compound

• Related Pathways :

  PI3K/Akt/mTOR; PROTAC

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ms15-tfa.html

• Purity :

  99.86

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  NC1(CCC1)C(C=C2)=CC=C2N3C4=NC(C5=CC(CCC(NCCCCCCCCCCC(N[C@H](C(N6C[C@@H](C[C@H]6C(N[C@@H](C)C7=CC=C(C=C7)C8=C(N=CS8)C)=O)O)=O)C(C)(C)C)=O)=O)=CC=C5)=CC=C4N=C3C9=CC=CN=C9N.OC(C(F)(F)F)=O

• Molecular Formula :

  C66H80F3N11O7S

• Molecular Weight :

  1228.47

• References & Citations :

  [1]Yu X, et al. Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells. J Med Chem. 2022 Oct 27;65 (20) :14237-14260.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  -80°C, protect from light, stored under nitrogen

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported